{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:06:42Z","timestamp":1786547202770,"version":"build-2736575974"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The Food and Drug Administration's (FDA) approval decisions are expected to rest primarily on clinical evidence, yet concerns persist about whether political pressure, commercial interests, or institutional dynamics also influence the approval process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a scoping review of empirical studies published between 1990 and 2025 evaluating factors other than clinical evidence in FDA drug approval decisions, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen studies examined 5 categories of factors: firm-level attributes, FDA organizational structures, procedural factors, regulatory reforms, and external pressures including media attention and political salience. Most studies (10\/15) evaluated these factors using speed of FDA drug approval as a primary outcome, rather than the decision to approve or reject, or a measure of decision quality. Findings were mixed, with the most consistent evidence for close agreement between advisory committee recommendations and approval decisions, identified across independent research teams. More limited evidence also suggested external stakeholder pressure may affect review times.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A paucity of empirical evidence likely points to the inherent difficulty of demonstrating influence on agency decision-making. More research is needed to evaluate the potential influence of factors beyond clinical evidence on approval decisions, and the extent to which these decisions ultimately benefit patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/haschl\/qxag201","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:12:59Z","timestamp":1785831179000},"source":"Crossref","is-referenced-by-count":0,"title":["Factors influencing FDA drug approval decisions beyond clinical trial evidence: a scoping review"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2464-7182","authenticated-orcid":false,"given":"Robin","family":"Forrest","sequence":"first","affiliation":[{"name":"Department of Health Policy, The London School of Economics , London WC2A 2AE ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4273-6118","authenticated-orcid":false,"given":"Martin","family":"Lodge","sequence":"additional","affiliation":[{"name":"Department of Government and Centre for Analysis of Risk and Regulation, The London School of Economics , London WC2A 2AE ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5043-6206","authenticated-orcid":false,"given":"Ameet","family":"Sarpatwari","sequence":"additional","affiliation":[{"name":"Harvard Pilgrim Health Care Institute and Harvard Medical School , Boston ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7192-5751","authenticated-orcid":false,"given":"Huseyin","family":"Naci","sequence":"additional","affiliation":[{"name":"Department of Health Policy, The London School of Economics , London WC2A 2AE ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"2026081210080429600_qxag201-B1","author":"Food and Drug Administration"},{"issue":"24","key":"2026081210080429600_qxag201-B2","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMp0903764","article-title":"The FDA as a public health agency","volume":"360","author":"Hamburg","year":"2009","journal-title":"N Engl J Med"},{"issue":"6441","key":"2026081210080429600_qxag201-B3","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1126\/science.aaw8093","article-title":"When science and politics collide: enhancing the FDA","volume":"364","author":"Adashi","year":"2019","journal-title":"Science"},{"key":"2026081210080429600_qxag201-B4","author":"Herper"},{"issue":"11","key":"2026081210080429600_qxag201-B5","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/nbt.3733","article-title":"Railroading at the FDA","volume":"34","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2026081210080429600_qxag201-B6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer's disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol"},{"issue":"7863","key":"2026081210080429600_qxag201-B7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/d41586-021-01546-2","article-title":"Landmark Alzheimer's drug approval confounds research community","volume":"594","author":"Mullard","year":"2021","journal-title":"Nature"},{"key":"2026081210080429600_qxag201-B8"},{"key":"2026081210080429600_qxag201-B9"},{"key":"2026081210080429600_qxag201-B10","author":"Kesselheim"},{"key":"2026081210080429600_qxag201-B11","author":"Brownlee"},{"key":"2026081210080429600_qxag201-B12","author":"Mazer"},{"key":"2026081210080429600_qxag201-B13","author":"Carpenter"},{"key":"2026081210080429600_qxag201-B14","author":"U.S. Committees on Oversight and Reform"},{"issue":"4","key":"2026081210080429600_qxag201-B15","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1017\/jme.2024.20","article-title":"Aducanumab, accelerated approvals & the agency: why the FDA needs structural reform","volume":"51","author":"Herder","year":"2023","journal-title":"J Law Med Ethics"},{"key":"2026081210080429600_qxag201-B16","author":"Bell"},{"issue":"2","key":"2026081210080429600_qxag201-B17","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/cpt.3292","article-title":"Trust in the Food and Drug Administration: a national survey study","volume":"116","author":"Feldman","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"S2","key":"2026081210080429600_qxag201-B18","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1002\/hast.1525","article-title":"Securing the trustworthiness of the FDA to build public trust in vaccines","volume":"53","author":"Rand","year":"2023","journal-title":"Hastings Cent Rep"},{"issue":"12","key":"2026081210080429600_qxag201-B19","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1001\/jamainternmed.2021.6045","article-title":"FDA drug approval and the ethics of desperation","volume":"181","author":"Largent","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"1","key":"2026081210080429600_qxag201-B20","doi-asserted-by":"publisher","DOI":"10.1093\/haschl\/qxag013","article-title":"The Food and Drug Administration's role in supporting therapeutic development to address unmet needs: the national academies report and beyond","volume":"4","author":"Dhruva","year":"2026","journal-title":"Health Aff Sch."},{"issue":"2","key":"2026081210080429600_qxag201-B21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2019.20288","article-title":"FDA approval and regulation of pharmaceuticals, 1983-2018","volume":"323","author":"Darrow","year":"2020","journal-title":"JAMA"},{"issue":"23","key":"2026081210080429600_qxag201-B22","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1056\/NEJMhle1710706","article-title":"Speed, safety, and industry funding\u2014from PDUFA I to PDUFA VI","volume":"377","author":"Darrow","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"2026081210080429600_qxag201-B23","doi-asserted-by":"publisher","first-page":"e231313","DOI":"10.1001\/jamahealthforum.2023.1313","article-title":"Extending the US Food and Drug Administration's postmarket authorities","volume":"4","author":"Fernandez Lynch","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"4","key":"2026081210080429600_qxag201-B24","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1001\/jama.2013.282034","article-title":"Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012","volume":"311","author":"Downing","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"2026081210080429600_qxag201-B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3284","article-title":"Assessment of clinical trials supporting US Food and Drug Administration approval of novel therapeutic agents, 1995-2017","volume":"3","author":"Zhang","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2026081210080429600_qxag201-B26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1215\/03616878-10041093","article-title":"Trends in the quality of evidence supporting FDA drug approvals: results from a literature review","volume":"47","author":"Brown","year":"2022","journal-title":"J Health Polit Policy Law"},{"key":"2026081210080429600_qxag201-B27","doi-asserted-by":"crossref","DOI":"10.1093\/acprof:osobl\/9780199576081.001.0001","volume-title":"Understanding Regulation: Theory, Strategy, and Practice","author":"Baldwin","year":"2011"},{"issue":"special","key":"2026081210080429600_qxag201-B28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/jleo\/6.special_issue.167","article-title":"Regulatory capture, public interest, and the public agenda: toward a synthesis","volume":"6","author":"Levine","year":"1990","journal-title":"J Law Econ Organ"},{"issue":"1","key":"2026081210080429600_qxag201-B29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2307\/3003160","article-title":"The theory of economic regulation","volume":"2","author":"Stigler","year":"1971","journal-title":"Bell J Econ Manag Sci"},{"issue":"2","key":"2026081210080429600_qxag201-B30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/oxrep\/grj013","article-title":"Regulatory capture: a review","volume":"22","author":"Dal B\u00f3","year":"2006","journal-title":"Oxf Rev Econ Policy"},{"key":"2026081210080429600_qxag201-B31","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9781139565875","volume-title":"Preventing Regulatory Capture: Special Interest Influence and how to Limit it","author":"Carpenter","year":"2013"},{"key":"2026081210080429600_qxag201-B32","author":"Lupkin"},{"key":"2026081210080429600_qxag201-B33","author":"BMJ Groups"},{"issue":"1","key":"2026081210080429600_qxag201-B34","first-page":"1","article-title":"FDA's revolving door: reckoning and reform","volume":"34","author":"Karas","year":"2023","journal-title":"Stanf Law Policy Rev"},{"issue":"1","key":"2026081210080429600_qxag201-B35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12910-023-00921-0","article-title":"The effects of lobbying on the FDA's recall classification","volume":"24","author":"Zhou","year":"2023","journal-title":"BMC Med Ethics"},{"issue":"3","key":"2026081210080429600_qxag201-B36","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamainternmed.2016.8443","article-title":"Patient advocacy organizations, industry funding, and conflicts of interest","volume":"177","author":"Rose","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2026081210080429600_qxag201-B37","volume-title":"Reputation and Power","author":"Carpenter","year":"2010"},{"key":"2026081210080429600_qxag201-B38","doi-asserted-by":"crossref","DOI":"10.1093\/oxfordhb\/9780199560219.001.0001","volume-title":"The Oxford Handbook of Regulation","author":"Baldwin","year":"2010"},{"key":"2026081210080429600_qxag201-B39","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-137-26552-4","volume-title":"Managing Regulation: Regulatory Analysis, Politics and Policy","author":"Lodge","year":"2012"},{"issue":"7","key":"2026081210080429600_qxag201-B40","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"2026081210080429600_qxag201-B41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Methodol"},{"key":"2026081210080429600_qxag201-B42","doi-asserted-by":"crossref","DOI":"10.46658\/JBIMES-24-01","volume-title":"JBI manual for Evidence Synthesis","author":"Aromataris","year":"2024"},{"issue":"7","key":"2026081210080429600_qxag201-B43","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1001\/jama.2017.9415","article-title":"Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration","volume":"318","author":"Naci","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"2026081210080429600_qxag201-B44","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1001\/jama.2018.7619","article-title":"Clinical trial evidence supporting FDA approval of drugs granted breakthrough therapy designation","volume":"320","author":"Puthumana","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"2026081210080429600_qxag201-B45","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1430-9134.1997.00377.x","article-title":"Firm characteristics and the speed of FDA approval","volume":"6","author":"Olson","year":"1997","journal-title":"J Econ Manag Strategy"},{"issue":"3","key":"2026081210080429600_qxag201-B46","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1430-9134.2000.00363.x","article-title":"Regulatory reform and bureaucratic responsiveness to firms: the impact of user fees in the FDA","volume":"9","author":"Olson","year":"2000","journal-title":"J Econ Manag Strategy"},{"issue":"3","key":"2026081210080429600_qxag201-B47","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2307\/3088394","article-title":"Groups, the media, agency waiting costs, and FDA drug approval","volume":"46","author":"Carpenter","year":"2002","journal-title":"Am J Polit Sci"},{"issue":"Suppl 1","key":"2026081210080429600_qxag201-B48","doi-asserted-by":"publisher","first-page":"W3","DOI":"10.1377\/hlthaff.W3.618","article-title":"Approval times for new drugs: does the source of funding for FDA staff matter?","volume":"22","author":"Carpenter","year":"2003","journal-title":"Health Aff (Millwood)"},{"issue":"3","key":"2026081210080429600_qxag201-B49","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1215\/03616878-29-3-397","article-title":"Managing delegation in the FDA: reducing delay in new-drug review","volume":"29","author":"Olson","year":"2004","journal-title":"J Health Polit Policy Law"},{"issue":"3","key":"2026081210080429600_qxag201-B50","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/jleo\/ewp002","article-title":"Early entrant protection in approval regulation: theory and evidence from FDA drug review","volume":"26","author":"Carpenter","year":"2010","journal-title":"J Law Econ Organ"},{"issue":"2","key":"2026081210080429600_qxag201-B51","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/jopart\/muq046","article-title":"Federal advisory committees, policy expertise, and the approval of drugs and medical devices at the FDA","volume":"21","author":"Lavertu","year":"2011","journal-title":"J Public Adm Res Theory"},{"issue":"1","key":"2026081210080429600_qxag201-B52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1540-5907.2011.00544.x","article-title":"The complications of controlling agency time discretion: FDA review deadlines and postmarket drug safety","volume":"56","author":"Carpenter","year":"2012","journal-title":"Am J Polit Sci"},{"issue":"2","key":"2026081210080429600_qxag201-B53","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/1476127012444917","article-title":"Arbiter of science: institutionalization and status effects in FDA drug review 1990\u20132004","volume":"10","author":"Kim","year":"2012","journal-title":"Strateg Organ"},{"issue":"1","key":"2026081210080429600_qxag201-B54","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/annonc\/mdt512","article-title":"How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers' views","volume":"25","author":"Tafuri","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"2026081210080429600_qxag201-B55","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jamaoncol.2015.6479","article-title":"Oncologic drugs advisory committee recommendations and approval of cancer drugs by the US Food and Drug Administration","volume":"2","author":"Tibau","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5","key":"2026081210080429600_qxag201-B56","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.japh.2018.05.017","article-title":"United States Food and Drug Administration Advisory Committee outcomes and agency approval analysis from 2010 to 2015","volume":"58","author":"McCormack","year":"2018","journal-title":"J Am Pharm Assoc"},{"issue":"3","key":"2026081210080429600_qxag201-B57","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/1468-0009.12403","article-title":"Association between Food and Drug Administration Advisory Committee recommendations and agency actions, 2008\u20132015","volume":"97","author":"Zhang","year":"2019","journal-title":"Milbank Q"},{"issue":"7","key":"2026081210080429600_qxag201-B58","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.1718","article-title":"Association of advisory committee votes with US Food and Drug Administration decision-making on prescription drugs, 2010-2021","volume":"4","author":"Daval","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"11","key":"2026081210080429600_qxag201-B59","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1038\/s41591-024-03242-w","article-title":"The role of FDA advisory committees","volume":"30","author":"Helms Williams","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"2026081210080429600_qxag201-B60","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1377\/hlthaff.2021.01927","article-title":"Unwanted advice? Frequency, characteristics, and outcomes of negative advisory committee votes for FDA-approved drugs","volume":"41","author":"Daval","year":"2022","journal-title":"Health Aff Proj Hope"},{"issue":"3","key":"2026081210080429600_qxag201-B61","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1017\/S002238161000023X","article-title":"Promoting agency reputation through public advice: advisory committee use in the FDA","volume":"72","author":"Moffitt","year":"2010","journal-title":"J Polit"},{"issue":"9","key":"2026081210080429600_qxag201-B62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002873","article-title":"The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: a cross-sectional study of products authorised 2011-2018","volume":"16","author":"Schuster Bruce","year":"2019","journal-title":"PLoS Med"},{"key":"2026081210080429600_qxag201-B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100332","article-title":"Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs","volume":"21","author":"Gyawali","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2026081210080429600_qxag201-B64","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q1418","article-title":"Revolving door: you are free to influence us \u201cbehind the scenes,\u201d FDA tells staff leaving for industry jobs","volume":"386","author":"Doshi","year":"2024","journal-title":"BMJ"},{"issue":"12","key":"2026081210080429600_qxag201-B65","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S1470-2045(24)00596-5","article-title":"Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment","volume":"25","author":"Forrest","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"2026081210080429600_qxag201-B66","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.17450","article-title":"Patient perspectives on approval speed vs evidentiary certainty in US cancer drug approvals","volume":"9","author":"Forrest","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"17","key":"2026081210080429600_qxag201-B67","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jama.2024.2396","article-title":"Clinical benefit and regulatory outcomes of cancer drugs receiving accelerated approval","volume":"331","author":"Liu","year":"2024","journal-title":"JAMA"}],"container-title":["Health Affairs Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/advance-article-pdf\/doi\/10.1093\/haschl\/qxag201\/70475964\/qxag201.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/4\/8\/qxag201\/70475964\/qxag201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/4\/8\/qxag201\/70475964\/qxag201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:08:58Z","timestamp":1786543738000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article\/doi\/10.1093\/haschl\/qxag201\/8750773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/haschl\/qxag201","relation":{},"ISSN":["2976-5390"],"issn-type":[{"value":"2976-5390","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8]]},"article-number":"qxag201"}}